compani
catalyst ahead earn
messag eli lilli stock pressur despit strong earn
believ may relat problem lli anim health busi
spin-out divestitur decis anticip mid-year accord compani
regardless believ three import upcom potenti catalyst propel
growth rate name potenti baricitinib approv rewind
cv result trulic verzenio label expans expect
glacanezumab anti-crgp antibodi migrain prevent approv later
year
manag call investor stock trade greater drg
index less difficult pinpoint particular issu creat investor
dyspepsia one subject may relat anim health ah busi decis
spin-out divestitur elanco ah busi anticip mid-year
question call relat whether busi could essenti stand alon
given busi approxim sale revenu growth yoy appear
challeng
launch uptak olumi baricitinb germani strong see previou
note januari compar histor humira rheumatoid arthriti
believ launch trajectori would repeat howev may depend
black box warn pertain thromboembol fda advisori committe
meet baricitinib expect manag state call
timelin remain unknown accord manag advisori committe
expect discuss safeti problem beyond deep vein thrombosi believ
chanc black box warn low pleas rememb german label contain
warn deep vein thrombosi emphas highlight among
warn furthermor german label also contain dose
manag state major patient use dose call
manag provid background inform clinic trial death
two report death patient pulmonari embol clinic trial program
one death occur baricitinib group day first dose one
death occur methotrex group day methotrex treatment
resubmit data packag contain clinic trial extens studi found
dose incid dvt pe well
accord manag incid well within rang background rate
ra overal believ label resembl german label
expect similar launch trajectori
lli focu remain larg diabet franchis evidenc trulic qoq
growth driven increas market share growth class
provid competit trulic demonstr differ
label call manag said well prepar ozemp launch
outcom rewind crucial trulic growth potenti inde manag
state cv outcom benefit increasingli import beyond trulic
current develop two agent treatment diabet see previou note
page analyst certif import disclosur
pertain oncolog see launch verzenio posit particularli
thu far indic roughli one-third relev patient popul
compet inhibitor indic manag hope launch largest
indic combin aromatas inhibitor later pdufa april
last two year market growth psoriasi compar singl
digit growth accord manag newer agent taltz increas
expect physician term efficaci lead faster switch older
agent manag seem excit launch taltz psoriat
arthriti ran separ trial patient yet receiv biolog
advanc therapi alreadi use one treatment often anti-
tnf med like humira enabl give doctor inform
specif patient may get prescrib taltz compet product
novarti nv cosentyx addit pursu market strategi via
rheumatologist believ rheumatologist prone prescrib
biolog dermatologist call manag note cosentyx script
written dermatologist due patient continu turn see
patient access problem continu see taltz revenu growth qoq
import lli overal revenu growth
made adjust model base result updat guidanc
manag commentari compani earn call made
adjust effect tax rate subsequ year result recent
tax reform legisl model tax rate
assumpt may abl lower tax rate futur year
adjust revenu estim increas
respect ep estim increas
primarili driven decreas tax rate
valuat risk
valuat reiter price target use dcf analysi use
long-term growth rate unchang wacc calcul use risk-
free rate equiti risk premium maintain buy rate base
approv abemaciclib expect abemaciclib approv front line set
uptak recent launch product taltz trulic jardianc go forward strong
expect growth class diabet drug improv
oper effici futur year
risk risk rate estim pt includ higher-than-anticip oper
expens new product launch may poorli expect higher
expens lower revenu may lead lower profit manag care could
push back rel price new brand product may affect assumpt
futur revenu final area includ diabet oncolog much
competit may slow initi demand new product
page analyst certif import disclosur
million except per-shar figur
adjust dilut ep excl amort intang
page analyst certif import disclosur
